Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of GBS-NN/NN2 vaccine regimens in pregnant women
2021-003214-40Phase 2Completed
- Sponsor
- MinervaX
- Start
- Jul 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of GBS-NN/NN2 vaccine in Streptococcus agalactiae infection (GBS) and neonatal sepsis (5 arms), sponsored by MinervaX. Primary endpoint: Cord blood IgG specific to AlpN proteins. Started Jul 2021; status: completed.
02
Drugs
GBS-NN/NN2 vaccine
03
Conditions
Streptococcus agalactiae infection (GBS)neonatal sepsis
Beyond the preview
Go deeper on 2021-003214-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003214-40.